Global Enasidenib Market Size By Type (50mg, 100mg), By Application (Hospital, Pharmacy), By Region, And Segment Forecasts, 2023 to 2032

The Global Enasidenib Market was valued at USD 620 million in 2023 and is projected to surpass USD 1.14 billion by 2031, growing at a CAGR of 7.9% during the forecast period from 2023 to 2031. Enasidenib, an isocitrate dehydrogenase-2 (IDH2) inhibitor, is primarily used for the treatment of relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutation. The market growth is propelled by increasing incidences of AML, growing demand for targeted cancer therapies, and supportive regulatory frameworks facilitating expedited drug approvals. The continued advancement in molecular diagnostics and personalized medicine is also fueling the adoption of enasidenib globally.

Drivers:

1. Rising Incidence of Acute Myeloid Leukemia (AML):

The increasing prevalence of AML worldwide, especially among the aging population, is a key factor driving the demand for effective treatment options like enasidenib.

2. Shift Toward Targeted Therapies:

Healthcare providers and patients are increasingly preferring targeted therapies over conventional chemotherapy due to higher efficacy and lower toxicity. Enasidenib’s mechanism of targeting IDH2 mutations aligns with this trend, supporting its market penetration.

3. Regulatory Support for Orphan Drugs:

Enasidenib has received orphan drug status in several regions including the U.S. and Europe, granting market exclusivity and encouraging R&D investment in its expanded indications.

Restraints:

1. High Cost of Therapy:

The high cost of enasidenib treatment can limit access, particularly in low- and middle-income countries, impacting overall market growth.

2. Limited Awareness and Diagnosis:

Accurate detection of IDH2 mutations is critical for enasidenib administration. Inadequate access to advanced diagnostic testing in some regions can hinder market uptake.

Opportunity:

1. Expansion into Emerging Markets:

Emerging economies, especially in Asia-Pacific and Latin America, present lucrative growth opportunities with their expanding healthcare infrastructure and increasing investment in oncology.

2. Broader Therapeutic Applications:

Ongoing clinical trials are investigating the use of enasidenib in combination therapies and in earlier stages of AML or other IDH2-mutant malignancies, potentially broadening its application scope.

Market by System Type Insights:

The market is segmented based on formulation, with the oral tablet segment dominating in 2023. Its convenience, non-invasive administration, and patient compliance advantages contribute to its wide adoption. The trend is expected to continue through 2031.

Market by End-use Insights:

In 2023, the hospital pharmacy segment held the largest market share. Due to the critical nature of AML treatment and need for continuous monitoring, most prescriptions and distributions of enasidenib are channeled through hospital settings. Specialty pharmacies are expected to witness notable growth as outpatient treatments rise.

Market by Regional Insights:

North America dominated the global enasidenib market in 2023 due to its robust healthcare infrastructure, high prevalence of AML, and strong presence of pharmaceutical players. However, Asia-Pacific is projected to grow at the fastest rate through 2031, driven by increased cancer awareness, improving diagnostic capabilities, and growing healthcare expenditure.

Competitive Scenario:

Key players in the enasidenib market include Servier Pharmaceuticals, Celgene Corporation (a Bristol-Myers Squibb company), AbbVie Inc., Agios Pharmaceuticals, and Roche Holding AG. Companies are focusing on clinical development, strategic collaborations, and geographic expansion. For instance:

In 2024, Agios Pharmaceuticals announced promising Phase II trial results for enasidenib in combination with azacitidine, targeting front-line AML treatment.

Servier expanded its manufacturing capabilities in 2023 to support growing global demand for enasidenib.

Bristol-Myers Squibb is exploring label expansion strategies and combination therapy approvals for broader AML indications.

Scope of Work – Global Enasidenib Market

Key Market Developments:

March 2023: FDA granted Breakthrough Therapy Designation for enasidenib in combination with venetoclax for treatment-naïve AML patients with IDH2 mutation.

September 2024: Servier announced global licensing collaboration with a biotech firm to co-develop next-generation IDH inhibitors.

May 2025: Celgene expanded its precision oncology pipeline with digital biomarker tools for identifying suitable enasidenib responders.

FAQs:

What is the current market size of the Global Enasidenib Market?

The market was valued at USD 620 million in 2023.

What is the major growth driver of the Global Enasidenib Market?

The increasing incidence of acute myeloid leukemia and rising adoption of targeted therapies are the primary growth drivers.

Which is the largest region during the forecast period in the Global Enasidenib Market?

North America is expected to remain the largest region due to advanced healthcare systems and high AML diagnosis rates.

Which segment accounted for the largest market share in the Global Enasidenib Market?

The hospital pharmacy segment accounted for the largest market share in 2023.

Who are the key market players in the Global Enasidenib Market?

Servier Pharmaceuticals, Celgene Corporation, AbbVie Inc., Agios Pharmaceuticals, and Roche Holding AG are key players.